EYPT EyePoint, Inc.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1314102 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-93.9%
TTM net income YoY-66.5%
TTM EPS YoY-32.3%
Revenue 3-yr CAGR-60.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-13,642.0%
Net margin-13,281.2%
FCF margin-11,599.4%
EBITDA margin-13,533.9%
Returns
ROE-221.9%
ROA-164.0%
ROIC (approx.)-368.4%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets34.7%
Debt / equity0.00x
Current ratio3.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-22.9%
Payout ratio—
Capex / revenue170.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $31.37M | $43.27M |
| R&D expense | $221.04M | $132.93M |
| SG&A expense | $51.61M | $52.36M |
| Operating income | -$243.43M | -$145.85M |
| Interest expense | $33,000 | $14,000 |
| Pretax income | -$231.68M | -$130.78M |
| Income tax | $279,000 | $90,000 |
| Net income | -$231.96M | -$130.87M |
| EBITDA | -$241.12M | -$144.31M |
| EPS (basic) | -3.17 | -2.32 |
| EPS (diluted) | -3.17 | -2.32 |
| Weighted avg. shares (diluted) | 73,251 | 56,298 |
| Balance sheet | ||
| Cash & equivalents | $101.82M | $99.85M |
| Short-term investments | $204.26M | $271.21M |
| Inventory | $1.81M | $2.31M |
| Current assets | $328.65M | $383.31M |
| PP&E, net | $9.02M | $8.18M |
| Total assets | $364.00M | $418.46M |
| Current liabilities | $37.02M | $49.05M |
| Total liabilities | $57.88M | $81.96M |
| Shareholders' equity | $306.11M | $336.50M |
| Shares outstanding | 82.83M | 68.27M |
| Cash flow statement | ||
| Operating cash flow | -$240.11M | -$126.23M |
| Capital expenditure | $3.28M | $4.05M |
| Free cash flow | -$243.39M | -$130.28M |
| Investing cash flow | $68.58M | -$219.35M |
| Financing cash flow | $173.65M | $164.02M |
| Depreciation & amortization | $2.31M | $1.54M |
| Stock-based compensation | $27.87M | $36.74M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.